Delayed FDA action on CBD faces scrutiny as House hearing revives regulatory hopes
After years of delay, frustration, and regulatory ambiguity, the U.S. House Oversight Committee is hold a hearing this week that stakeholders hope will mark a turning point for the embattled […]
Delayed FDA action on CBD faces scrutiny as House hearing revives regulatory hopes Read More »